Market Overview

UPDATE: Morgan Stanley Reiterates On Cardinal Health Following CEO Conference Call

Related CAH
Who Will Feel The Pain From Generic Drug Price Inflation?
#PreMarket Primer: Friday, October 31: BOJ Spooked By Lackluster Growth And Inflation

In a report published Wednesday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Cardinal Health (NYSE: CAH), but removed the $76.00 price target.

In the report, Morgan Stanley noted, “Utilization trends likely positive for pharmaceutical segment; medical trends less clear. While George [Barrett, Cardinal Health CEO] did not comment on current quarter trends, he acknowledged that IMS Rx data (pointing to an improving trend for NRx in April) serves as a good proxy to assess directional script trends for CAH & large wholesalers.

"Conversely, medical segment is not well correlated with IMS data. CAH expects to continue to see fluctuations in segment demand driven by benefit design and greater consumer accountability.”

Cardinal Health closed on Tuesday at $71.10.

Latest Ratings for CAH

DateFirmActionFromTo
Nov 2014BarclaysMaintainsOverweight
Oct 2014CitigroupMaintainsNeutral
Oct 2014Credit SuisseMaintainsOutperform

View More Analyst Ratings for CAH
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

 

Related Articles (CAH)

Around the Web, We're Loving...

Get Benzinga's Newsletters